Statin therapy and the incidence of atherosclerotic cardiovascular events after kidney transplantation.

cardiovascular events kidney transplant recipients pharmacoepidemiology pharmacovigilance statins

Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
03 Oct 2023
Historique:
medline: 4 10 2023
pubmed: 4 10 2023
entrez: 4 10 2023
Statut: aheadofprint

Résumé

Statins are recommended in kidney transplant recipients (KTRs) - a population with a high risk of major cardiovascular (CV) events. However, the literature data on the effectiveness of statins in KTRs are sparse and inconclusive. The present study's objective was to evaluate the association between statin exposure and atherosclerotic CV events in KTRs and the biochemical effectiveness of statins on the lipid profile. 318 consecutive KTRs managed at a single center between 2006 and 2019 were retrospectively included. Those exposed to statins after transplantation were incident users. In all users, statins were indicated for primary CV prevention. Lipid profiles, the occurrence of any atherosclerotic CV events (stroke, myocardial infarction, other atherosclerotic CV events, and atherosclerotic CV deaths) were documented comprehensively. We applied Cox models that included statin exposure as a time-dependent covariate fitted with time-varying inverse probability treatment weighting (IPTW) to assess the effectiveness of statins on atherosclerotic CV events and on all CV events. We built linear mixed models to assess the biochemical effectiveness of statins. During a median [interquartile range] follow-up period of 6.0 [3.9-10.0] years, 27 atherosclerotic CV events occurred in 26 patients. In the Cox models fitted with time-varying IPTW, exposure to statins was not associated with a decrease in atherosclerotic CV events; the hazard ratio (HR) [95% confidence interval (CI)] was 1.16 [0.53-2.53] (p=0.700). In the linear mixed models, statin exposure was associated with significant decrease over time in triglyceride and low-density lipoprotein cholesterol concentrations (p < 0.001). These results were consistent when stratified for the intensity of statin therapy. Even though the lipid profile improved, statin exposure was not associated with a decrease in CV events in this real-life, single-center, retrospective, long-term follow-up study of a KTR cohort. Larger, controlled studies are needed to confirm or refute these results.

Sections du résumé

BACKGROUND BACKGROUND
Statins are recommended in kidney transplant recipients (KTRs) - a population with a high risk of major cardiovascular (CV) events. However, the literature data on the effectiveness of statins in KTRs are sparse and inconclusive. The present study's objective was to evaluate the association between statin exposure and atherosclerotic CV events in KTRs and the biochemical effectiveness of statins on the lipid profile.
METHODS METHODS
318 consecutive KTRs managed at a single center between 2006 and 2019 were retrospectively included. Those exposed to statins after transplantation were incident users. In all users, statins were indicated for primary CV prevention. Lipid profiles, the occurrence of any atherosclerotic CV events (stroke, myocardial infarction, other atherosclerotic CV events, and atherosclerotic CV deaths) were documented comprehensively. We applied Cox models that included statin exposure as a time-dependent covariate fitted with time-varying inverse probability treatment weighting (IPTW) to assess the effectiveness of statins on atherosclerotic CV events and on all CV events. We built linear mixed models to assess the biochemical effectiveness of statins.
RESULTS RESULTS
During a median [interquartile range] follow-up period of 6.0 [3.9-10.0] years, 27 atherosclerotic CV events occurred in 26 patients. In the Cox models fitted with time-varying IPTW, exposure to statins was not associated with a decrease in atherosclerotic CV events; the hazard ratio (HR) [95% confidence interval (CI)] was 1.16 [0.53-2.53] (p=0.700). In the linear mixed models, statin exposure was associated with significant decrease over time in triglyceride and low-density lipoprotein cholesterol concentrations (p < 0.001). These results were consistent when stratified for the intensity of statin therapy.
CONCLUSION CONCLUSIONS
Even though the lipid profile improved, statin exposure was not associated with a decrease in CV events in this real-life, single-center, retrospective, long-term follow-up study of a KTR cohort. Larger, controlled studies are needed to confirm or refute these results.

Identifiants

pubmed: 37791395
pii: 7288663
doi: 10.1093/ndt/gfad217
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.

Auteurs

Charifa Nazoiri (C)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.

Sophie Liabeuf (S)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.
MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.

François Brazier (F)

MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.
Department of Nephrology Internal Medicine Dialysis Transplantation, Amiens University Medical Center, Amiens, France.

Alban Nowak (A)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.

Youssef Bennis (Y)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.
MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.

Solène M Laville (SM)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.
MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.

Sandra Bodeau (S)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.
MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.

Valérie Gras-Champel (V)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.
MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.

Kamel Masmoudi (K)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.

Gabriel Choukroun (G)

MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.
Department of Nephrology Internal Medicine Dialysis Transplantation, Amiens University Medical Center, Amiens, France.

Benjamin Batteux (B)

Department of Pharmacology, Amiens University Medical Center, Amiens, France.
MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.
Department of Rheumatology, Saint-Quentin Medical Center, Saint-Quentin, France.

Classifications MeSH